EUMOVATE Cream
EUMOVATE® Cream 1 EUMOVATE® Cream Clobetasone butyrate 0.05% w/w New Zealand Consumer Medicine Information . What is in this leaflet Please read this leaflet carefully
Download EUMOVATE Cream
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
DRUGS AND COSMETICS (2 ND AMENDMENT) RULES, 2006 …
rajswasthya.nic.in119. clindamycin 120. clobazam 121. clobetasol propenate 122. clobetasone 17-butyrate 123. clofazimine 124. clofibrate 125. clonazepam 126. clonidine hydrochloride
BNF 13: Skin Colchester Hospital University NHS Foundation ...
www.colchesterhospital.nhs.ukPage 1 of 6 BNF 13: Skin Last updated: thSeptember 12 2017 BNF 13: Skin . Colchester Hospital University NHS Foundation Trust does not currently have a Dermatology Department, nor any Dermatology Consultants.
Public Assessment Report Decentralised Procedure - GOV.UK
www.mhra.gov.ukPublic Assessment Report Decentralised Procedure CLOBAVATE 0.05% W/W OINTMENT (Clobetasone butyrate) Procedure No: UK/H/3212/001/DC UK Licence No: PL 17507/0118
Medicines in Schedule 1 to the Medicine Regulations 1984 ...
www.medsafe.govt.nzMedicines in Schedule 1 to the Medicine Regulations 1984 that reference the manufacturer’s original pack Information paper for the Medicines Classification
List of IP Reference Substances available at IPC, Ghaziabad
chromachemie.co.in* Valid upto last day of the month List of IP Reference Substances available at IPC, Ghaziabad S.No. Name of Reference Substance Current Lot No.